n the study, a team led by ICR researcher Paul Huang looked at tumors from nearly 2,000 breast cancer patients. They focused on HER-2 positive breast cancers, which account for about 20 percent of breast cancers.
Huang's team found that patients whose tumors had high activity in a gene called F12, but low activity in a gene called STC2, were three times more likely to die within 10 years, compared to patients with different patterns of activity in these two genes.
Read Full Article »